1. Disease Overview

Pulmonary valve disease affects the valve that sits between the right ventricle (the heart’s lower-right pumping chamber) and the pulmonary artery, which carries blood to the lungs to pick up oxygen. When this valve does not open or close properly, blood flow from the heart to the lungs is disrupted.

There are two main problems. Pulmonary stenosis is a narrowed valve that cannot open fully, so the right ventricle must work harder to push blood through. It is one of the most common congenital (present-at-birth) heart valve defects. Pulmonary regurgitation (also called pulmonary insufficiency) is a leaky valve that allows blood to flow backward into the right ventricle; it is most often seen years after surgical repair of Tetralogy of Fallot or other congenital procedures.

Mild disease often causes no symptoms and may be found only when a doctor hears a heart murmur. Moderate to severe disease can strain the right ventricle over time, leading to breathlessness, fatigue and, eventually, right-heart failure. Modern treatment is highly effective and increasingly minimally invasive, ranging from balloon valvuloplasty for stenosis to surgical or transcatheter pulmonary valve replacement (using devices such as Melody or Sapien valves). With timely care, the long-term outlook for most patients is excellent.

2. Key Facts at a Glance

Fact	Detail
Also known as	Pulmonic valve disease, pulmonary stenosis (PS), pulmonary regurgitation (PR), pulmonary insufficiency
Body system affected	Right heart and pulmonary circulation (right ventricle to lungs)
Common in	Newborns and children (stenosis); adults after congenital repair (regurgitation)
Severity range	Trivial and harmless to severe with right-heart failure
Key treatments	Monitoring, balloon valvuloplasty, surgical or transcatheter valve replacement
Outlook	Excellent with timely treatment; many patients live normal lifespans

3. Alternative Names and Medical Terminology

Pulmonary stenosis (PS) — narrowing of the valve; may be valvular, subvalvular (infundibular), or supravalvular.
Pulmonary regurgitation (PR) / pulmonary insufficiency — a leaking valve.
Pulmonic valve — an alternative spelling for the pulmonary valve.
Dysplastic pulmonary valve — thickened, immobile valve tissue seen in some congenital forms.
RVOT obstruction — right ventricular outflow tract obstruction, a broader term that includes valvular stenosis.
PVR / TPVR — pulmonary valve replacement / transcatheter pulmonary valve replacement.

4. Relevant Heart, Lung or Vascular Anatomy

The pulmonary valve is one of the heart’s four valves. It normally has three thin cusps (leaflets) that open to let deoxygenated blood pass from the right ventricle into the main pulmonary artery and close to prevent backflow.

Right ventricle (RV): the muscular chamber that pumps blood to the lungs; it is thinner-walled and lower-pressure than the left ventricle.
Right ventricular outflow tract (RVOT): the funnel-shaped channel leading up to the valve.
Pulmonary artery: divides into left and right branches to supply both lungs.

Because the RV is designed for low pressure, it is sensitive to the extra pressure load of stenosis and the volume load of regurgitation. Over time either can cause the RV to thicken, enlarge and weaken.

5. How the Disease Affects the Body

Pulmonary valve disease disturbs the right side of the heart in two distinct ways.

In pulmonary stenosis, the narrowed valve forces the right ventricle to generate much higher pressure to eject blood. This chronic pressure overload makes the RV muscle thicken (hypertrophy). Mild narrowing is well tolerated for decades, but severe stenosis eventually limits how much blood reaches the lungs during exertion, producing breathlessness and fatigue. Very tight stenosis in newborns can be a medical emergency because too little blood flows to the lungs.

In pulmonary regurgitation, the leaking valve lets blood flow backward into the RV with each heartbeat. The RV must then handle both its normal filling and the leaked blood — a chronic volume overload. The chamber dilates (enlarges) to accommodate the extra volume. For many years the RV copes silently, which is why severe PR is often “quiet.” But sustained dilation gradually impairs RV contraction, can trigger arrhythmias, and may lead to right-heart failure with swelling of the legs and abdomen.

Both problems can also affect the tricuspid valve (through RV enlargement) and reduce the heart’s overall exercise capacity. The key clinical goal is to intervene before RV damage becomes permanent.

6. Types and Classification

By lesion: pulmonary stenosis (obstruction) vs pulmonary regurgitation (leak); many patients have some of both, especially after repair.
By level of obstruction: valvular (the valve itself), subvalvular/infundibular (muscle below the valve), or supravalvular/branch (in the pulmonary artery).
By valve morphology: typical fused dome-shaped valve, dysplastic (thickened) valve, or bicuspid/unicuspid valve.
By cause: congenital (most cases) vs acquired (post-surgical, carcinoid, rheumatic, endocarditis).
By severity: graded mild, moderate or severe using echocardiographic gradients and jet measurements.

7. Causes of the Disease

Congenital malformation — the leading cause; the valve forms abnormally during fetal development.
As part of a syndrome — Tetralogy of Fallot, Noonan syndrome (often with a dysplastic valve), and Williams syndrome.
Post-surgical regurgitation — deliberate opening of the valve during Tetralogy of Fallot repair often leaves lifelong PR.
Carcinoid heart disease — hormone-secreting tumours can damage the right-sided valves.
Infective endocarditis — infection destroying valve tissue (uncommon on the pulmonary valve).
Rheumatic heart disease — rare on the pulmonary valve but possible.
Pulmonary hypertension — high lung-artery pressure can stretch the valve ring and cause a leak.

8. How the Disease Develops

Most pulmonary valve disease begins before birth. During early fetal development the valve cusps may fail to separate fully, remaining fused into a narrowed dome (stenosis), or the valve tissue may be thick and immobile (dysplastic). These defects are established at birth and typically detected in infancy or childhood through a murmur or during evaluation of a congenital syndrome.

Acquired disease develops later. The most common pathway is iatrogenic: to relieve obstruction during repair of Tetralogy of Fallot, surgeons open or patch the RVOT, which frequently leaves the valve incompetent. Chronic pulmonary regurgitation then slowly enlarges the right ventricle over years or decades.

Other acquired routes include carcinoid plaques stiffening the leaflets, bacterial infection eroding tissue, or a dilated pulmonary artery pulling the valve ring open. In all cases, the underlying process is a gradual change in RV loading — pressure with stenosis, volume with regurgitation — that the heart compensates for until compensation fails. Progression is usually slow, giving time for surveillance and well-timed intervention.

9. Risk Factors

Congenital heart conditions — especially Tetralogy of Fallot and other RVOT anomalies.
Prior heart surgery in childhood, particularly congenital repairs.
Family history of congenital heart disease.
Genetic syndromes — Noonan, Williams, Alagille, DiGeorge (22q11 deletion).
Maternal factors during pregnancy — rubella infection, certain medications, poorly controlled diabetes.
Carcinoid tumours — a risk for acquired right-sided valve disease.
History of endocarditis or indwelling cardiac devices.

10. Genetic and Family-History Factors

Pulmonary valve disease is often genetically influenced. Noonan syndrome, caused by mutations in the RAS-MAPK pathway (such as PTPN11), is classically associated with a thickened, dysplastic pulmonary valve. Williams syndrome (elastin gene deletion) can cause supravalvular and branch pulmonary artery stenosis. Tetralogy of Fallot and related lesions are more common in families with a history of congenital heart disease and in 22q11.2 deletion syndrome.

If a parent or sibling has congenital heart disease, the risk to offspring is modestly increased. Genetic counselling and fetal echocardiography are recommended for families with a known syndrome or a strong family history. Most isolated pulmonary stenosis, however, occurs without an identifiable single-gene cause.

11. Who Is Most at Risk?

Newborns and infants with congenital valve defects.
Children and adults who had Tetralogy of Fallot repaired — the group most likely to develop severe regurgitation.
People with Noonan or Williams syndrome.
Patients with a family history of congenital heart disease.
Individuals with carcinoid syndrome or prior endocarditis.
Babies of mothers who had rubella or poorly controlled diabetes during pregnancy.

12. Prevalence and Epidemiology

Pulmonary stenosis is one of the most common congenital heart defects, accounting for roughly 8–12% of all congenital heart lesions and affecting a small but meaningful share of newborns worldwide. Most cases are mild and are managed without intervention.

Pulmonary regurgitation as an isolated primary problem is uncommon, but it is very frequent as a late consequence of congenital repair — a large majority of adults who had Tetralogy of Fallot repaired in childhood develop significant PR over time. As survival after childhood congenital surgery has improved dramatically, a growing population of adults with congenital heart disease now requires lifelong monitoring. These figures are approximate and vary by region and reporting method.

13. Signs and Symptoms

Many people with mild pulmonary valve disease have no symptoms and feel entirely well; the condition is often discovered incidentally through a heart murmur. When symptoms do appear, they reflect a struggling right heart and reduced blood flow to the lungs.

Common symptoms include:

Shortness of breath, especially during exertion.
Fatigue and reduced exercise tolerance.
Palpitations or an irregular heartbeat.
Chest discomfort on activity.
Lightheadedness or, in severe cases, fainting (syncope).
Swelling of the ankles, legs or abdomen (a sign of right-heart strain).
In infants: poor feeding, rapid breathing, poor weight gain, and in severe cases a bluish tint to the skin (cyanosis).

Because severe regurgitation can be “silent” for years, the absence of symptoms does not always mean the heart is unaffected — which is why imaging surveillance matters.

14. Early-Stage Symptoms

Often completely asymptomatic; a murmur is the only clue.
Mild breathlessness noticed only with vigorous exercise.
Slightly reduced stamina compared with peers.
Occasional palpitations.
In children, subtle signs such as tiring more easily during play.

15. Advanced-Stage Symptoms

Marked breathlessness with everyday activity.
Persistent fatigue and exercise limitation.
Fainting or near-fainting, particularly on exertion (a warning sign in severe stenosis).
Leg, abdominal or facial swelling from right-heart failure.
Prominent neck veins and enlarged, tender liver.
Frequent or sustained arrhythmias, which can be dangerous in repaired congenital hearts.
Cyanosis in severe congenital cases.

16. Symptoms in Women, Men and Older Adults

Symptoms are broadly similar across sexes. Women with significant right-heart disease may first notice a decline in exercise tolerance during pregnancy, when blood volume rises and stresses the right ventricle. Men may be more likely to attribute early breathlessness to deconditioning and present later.

Older adults — often patients who had congenital repair decades earlier — may develop atrial arrhythmias, worsening breathlessness and fluid retention, and their symptoms can be confused with acquired coronary or left-heart disease. In the elderly, coexisting conditions can mask the right-heart origin of symptoms, so a careful cardiac evaluation is important.

17. Emergency Warning Signs

Seek emergency care for:

Fainting or collapse, especially during exertion.
Severe or sudden breathlessness or breathlessness at rest.
Chest pain with sweating or nausea.
A very fast, irregular or pounding heartbeat that does not settle.
In a newborn or infant: blue lips or skin, grunting, or severe difficulty feeding and breathing.

18. When to Seek Medical Help

Arrange a non-urgent medical review if you notice new or worsening breathlessness, falling exercise capacity, palpitations, or ankle swelling — particularly if you have a known valve problem or a history of congenital heart surgery. Anyone who had Tetralogy of Fallot or other congenital repair should stay under lifelong specialist follow-up even when feeling well, because severe regurgitation can be silent.

19. Disease Stages, Grades and Severity

Severity is graded mainly by echocardiography:

Pulmonary stenosis is classified by the peak pressure gradient across the valve: mild (roughly under 36 mmHg), moderate (about 36–64 mmHg), and severe (over 64 mmHg), with corresponding peak jet velocities.
Pulmonary regurgitation is graded trivial, mild, moderate or severe based on the width and depth of the backward jet, and on the size and function of the right ventricle.

Cardiac MRI provides the most accurate measure of regurgitant fraction and RV volumes, which are central to deciding when to treat. Severity, symptoms and RV size are considered together rather than any single number.

20. Disease Progression

Mild pulmonary stenosis often remains stable throughout life and may never need treatment. Moderate to severe stenosis tends to progress, thickening the right ventricle and, over years, limiting cardiac output.

Pulmonary regurgitation typically follows a slow but relentless course: the right ventricle gradually dilates over many years. There is a critical window — once RV enlargement passes a certain point, the chamber may not fully recover even after the valve is fixed. Progression accelerates once arrhythmias or overt right-heart failure appear. Careful serial imaging aims to intervene during the window when RV recovery is still possible.

21. Possible Complications

Right ventricular hypertrophy or dilation, leading to right-heart failure.
Arrhythmias — atrial flutter, atrial fibrillation, and dangerous ventricular arrhythmias (especially after Tetralogy of Fallot repair).
Sudden cardiac death — an uncommon but serious risk in some repaired congenital patients.
Tricuspid regurgitation from RV enlargement.
Infective endocarditis of the valve or a prosthesis.
Exercise intolerance and reduced quality of life.
Pulmonary artery aneurysm in some cases of chronic post-stenotic dilation.

Tetralogy of Fallot and other congenital outflow anomalies.
Ventricular septal defect and atrial septal defect.
Noonan, Williams, Alagille and DiGeorge syndromes.
Tricuspid valve disease from right-heart enlargement.
Pulmonary hypertension.
Carcinoid syndrome and infective endocarditis.
Atrial and ventricular arrhythmias.

23. Screening and Early Detection

Screening is targeted rather than population-wide. Fetal echocardiography can detect valve defects before birth in high-risk pregnancies (family history or known syndrome). In newborns, pulse oximetry screening and evaluation of any heart murmur help identify significant defects early.

Because a childhood murmur is often the first sign, prompt referral for echocardiography allows early diagnosis. For adults who had congenital repair, structured lifelong surveillance in an adult congenital heart disease clinic is the key form of “screening” for late regurgitation.

24. How the Disease Is Diagnosed

Diagnosis usually begins when a doctor hears a heart murmur or when a patient with a known congenital history is under routine review. The evaluation combines history, examination and imaging.

The echocardiogram (ultrasound of the heart) is the central test. It shows the valve’s structure, measures the pressure gradient across a stenotic valve, grades the severity of any regurgitation, and assesses the size and pumping function of the right ventricle. In many cases echo alone confirms the diagnosis and severity.

For regurgitation and for planning intervention, cardiac MRI is often decisive because it precisely quantifies the regurgitant fraction and RV volumes — the measurements that most influence timing of valve replacement. A CT scan may map the anatomy of the RVOT and pulmonary arteries before a transcatheter procedure. An ECG looks for right-heart strain and arrhythmias, and cardiac catheterization may directly measure pressures and is combined with treatment (balloon valvuloplasty) in some cases. The goal is to define the type, level and severity of disease and the condition of the right ventricle so that treatment can be timed correctly.

25. Physical Examination and Medical History

The doctor reviews any congenital diagnosis, prior surgery, syndromes and family history, then examines the heart. Characteristic findings include:

A systolic ejection murmur at the upper-left chest in stenosis, sometimes with a palpable thrill and a click.
A soft diastolic murmur in significant regurgitation.
A right ventricular heave and prominent neck veins with right-heart strain.
Signs of fluid overload — leg swelling, enlarged liver.
In infants, assessment of feeding, growth, breathing and skin colour.

26. Diagnostic Tests and Imaging

Echocardiogram — first-line; grades stenosis and regurgitation and assesses RV size/function.
Cardiac MRI — gold standard for quantifying regurgitant fraction and RV volumes.
Cardiac CT — detailed anatomy of the RVOT and pulmonary arteries for procedure planning.
ECG — right-axis deviation, RV hypertrophy, right bundle branch block, arrhythmias.
Chest X-ray — heart size, pulmonary artery contour.
Cardiac catheterization — direct pressure measurement; often combined with balloon treatment.
Cardiopulmonary exercise testing — objective exercise capacity, useful in follow-up.

27. Blood Tests, Biomarkers and Genetic Testing

There is no blood test that diagnoses pulmonary valve disease directly, but labs support overall assessment:

BNP / NT-proBNP — raised levels can indicate heart strain and help track right-heart failure.
Full blood count and metabolic panel — general fitness and pre-procedure workup.
Blood cultures — if endocarditis is suspected.
Genetic testing — considered when a syndrome (Noonan, Williams, 22q11 deletion) is suspected, and for family/reproductive counselling.

28. Understanding Test Results

In stenosis, a higher peak gradient / jet velocity means tighter narrowing; a gradient over ~64 mmHg indicates severe disease.
In regurgitation, a large regurgitant fraction on MRI and an enlarging, poorly contracting right ventricle indicate significant disease.
RV volumes on MRI are watched closely — reaching threshold values often signals that valve replacement should be considered even without symptoms.
Results are always interpreted together with symptoms and trend over time, not from one number in isolation. Your specialist will explain what your specific figures mean.

29. Differential Diagnosis

Conditions that can mimic or coexist with pulmonary valve disease include:

Atrial or ventricular septal defects (also produce murmurs and right-heart changes).
Pulmonary hypertension from lung disease or clots.
Tricuspid valve disease.
Innocent (functional) murmurs, common and harmless in children.
Right ventricular outflow obstruction at a subvalvular or supravalvular level.
Aortic stenosis or other left-sided murmurs radiating to the chest.

30. Specialist and Multidisciplinary Evaluation

Care is best delivered by a multidisciplinary heart team, especially for congenital cases. This typically includes an adult congenital heart disease (ACHD) or paediatric cardiologist, an interventional cardiologist, a congenital cardiac surgeon, cardiac imaging specialists, an electrophysiologist for arrhythmias, and specialist nurses. Anaesthetists and, when relevant, geneticists and obstetric-cardiology teams contribute. This team approach ensures the right procedure is chosen at the right time. Explore experienced doctors and specialist hospitals for congenital and valve care.

31. Treatment Goals

Relieve obstruction in stenosis to normalise RV pressure.
Eliminate or reduce regurgitation before the right ventricle is permanently damaged.
Preserve or restore RV size and function.
Prevent complications — heart failure, arrhythmias, sudden death and endocarditis.
Improve symptoms, exercise capacity and quality of life.
Choose the least invasive effective option and, where possible, delay or avoid repeat open surgery.

32. When Is Treatment Required?

Treatment is guided by severity, symptoms and RV status:

Severe stenosis (peak gradient over ~64 mmHg) usually warrants intervention even without symptoms; symptomatic moderate stenosis is also treated.
Severe regurgitation is treated when it causes symptoms, progressive RV dilation (RV volumes reaching guideline thresholds on MRI), declining RV function, or significant arrhythmias.
Mild disease is generally monitored, not treated.

Timing for regurgitation is a careful balance: intervening too early exposes patients to prosthesis-related issues, while waiting too long risks irreversible RV damage.

33. Active Monitoring and Watchful Waiting

Patients with mild or asymptomatic moderate disease are followed with periodic clinical review and imaging rather than immediate treatment. Typical surveillance includes regular echocardiograms, and cardiac MRI every 1–3 years for those with significant regurgitation to track RV volumes. Exercise testing and ECGs help detect early decline. The aim is to identify the optimal moment to intervene — before symptoms and irreversible RV enlargement develop. Patients are advised which symptoms should prompt earlier contact with their team.

34. Medications

There is no medication that cures pulmonary valve disease or replaces a mechanical fix, but drugs help manage symptoms and complications:

Diuretics — reduce fluid overload and swelling in right-heart failure.
Beta-blockers and antiarrhythmic drugs — control palpitations and arrhythmias.
Anticoagulants — for atrial fibrillation or certain prosthetic valves.
Medications for pulmonary hypertension — when that coexists.
Endocarditis prophylaxis (antibiotics) — advised for certain high-risk patients, including many with prosthetic valves, around dental and surgical procedures.

35. Minimally Invasive Treatments

For congenital pulmonary valve disease, the two least-invasive definitive treatments are catheter-based:

Balloon pulmonary valvuloplasty — a catheter with a balloon is threaded to the narrowed valve and inflated to split the fused leaflets. It is the treatment of choice for typical valvular pulmonary stenosis, often curative, with no chest incision and a short recovery.
Transcatheter pulmonary valve replacement (TPVR) — a new valve delivered by catheter for regurgitation or a failing conduit, avoiding open surgery.

These approaches offer faster recovery, smaller or no scars, and shorter hospital stays than surgery. Learn more about minimally invasive cardiac surgery.

36. Catheter-Based and Endovascular Treatments

Catheter-based therapy has transformed pulmonary valve care.

Balloon valvuloplasty relieves stenosis without surgery and is frequently the definitive treatment.
Transcatheter pulmonary valve replacement (TPVR) — devices such as the Melody valve (a bovine jugular valve on a stent) and the Edwards Sapien valve are implanted through a leg vein into the RVOT, most often to treat a failing surgical conduit or bioprosthesis, and increasingly in native or patched outflow tracts. Pre-stenting and careful anatomy assessment on CT are important.
Balloon angioplasty and stenting can treat branch pulmonary artery stenosis.

These options allow repeat valve treatments over a lifetime with minimal invasiveness. See catheter and stenting procedures.

37. Surgical Treatment Options

Surgery remains essential for anatomy unsuitable for catheter treatment and for many congenital reconstructions.

Surgical pulmonary valve replacement (PVR) is the standard operation for severe regurgitation and for stenosis not amenable to ballooning. Surgeons most often implant a bioprosthetic (tissue) valve or a valved conduit/homograft (a donor or animal pulmonary valve), because tissue valves in the pulmonary position last well and avoid the need for lifelong blood thinners. Mechanical valves are used only occasionally in this position.
Surgical valvotomy or RVOT reconstruction repairs a dysplastic valve or a narrowed outflow tract, sometimes with a transannular patch (which itself may leave regurgitation).
Concomitant procedures — tricuspid valve repair, closure of residual septal defects, and arrhythmia surgery (such as a cryoablation maze) are frequently performed at the same time in repaired congenital patients.

Modern surgery is very safe in experienced centres, and bioprosthetic pulmonary valves that later degenerate can often be treated with a valve-in-valve transcatheter procedure rather than repeat open surgery. Explore congenital heart procedures and specialist cardiac surgery options.

38. Advanced and Emerging Treatments

Self-expanding transcatheter valves designed for large, native RVOTs (e.g., Harmony, Alterra prestent systems) extend TPVR to patients previously needing open surgery.
Valve-in-valve TPVR to treat degenerated bioprostheses without reoperation.
Tissue-engineered and decellularised valves aiming for greater durability and growth potential in children.
3D printing and advanced imaging for precise procedural planning.
Improved arrhythmia mapping and ablation to reduce sudden-death risk in repaired congenital hearts.

39. Treatment Options Compared

Balloon valvuloplasty — best for typical valvular stenosis; low risk, quick recovery, often curative; not suitable for dysplastic valves or regurgitation.
Transcatheter valve replacement (Melody/Sapien) — treats regurgitation and failing conduits without open surgery; requires suitable anatomy; valves are durable but not permanent.
Surgical valve replacement — most versatile; handles any anatomy and allows concurrent repairs; involves open-heart surgery and longer recovery.
Surgical repair/RVOT reconstruction — preserves native tissue where possible.

The choice balances anatomy, severity, RV status, patient age and the goal of minimising invasiveness over a lifetime of care.

40. How Doctors Choose the Right Treatment

Key decision factors include:

Type and level of disease (stenosis vs regurgitation; valvular vs sub/supravalvular).
Valve and RVOT anatomy — whether it suits a catheter valve.
RV size and function on MRI and severity of the lesion.
Symptoms, arrhythmias and exercise capacity.
Patient age and likely need for future re-intervention.
Prior surgeries and presence of a conduit or bioprosthesis.
Patient preference and overall health.

The heart team weighs these to select the safest, most durable and least invasive effective option.

41. Benefits and Risks of Treatment

Benefits: relief of obstruction or leak, protection or recovery of the right ventricle, fewer arrhythmias, better exercise capacity, improved symptoms and quality of life, and lower long-term risk of heart failure.

Risks vary by procedure and are generally low in experienced centres:

Bleeding, infection, and anaesthetic risks.
Valve or conduit blockage during balloon or catheter work.
Device migration, stent fracture or leak with transcatheter valves.
Arrhythmias and, rarely, need for a pacemaker.
Prosthesis degeneration over years, requiring re-intervention.
Endocarditis of the new valve.

42. What Happens If the Disease Is Left Untreated?

Mild disease left untreated often causes no harm and simply needs monitoring. Untreated severe stenosis, however, progressively thickens and strains the right ventricle, reducing exercise capacity and eventually causing right-heart failure; critical stenosis in a newborn can be life-threatening.

Untreated severe regurgitation silently enlarges the right ventricle over years. If the window for intervention is missed, RV dilation and dysfunction can become irreversible, arrhythmias become more frequent and harder to treat, and the risk of sudden cardiac death rises. This is precisely why patients — even those feeling well — need lifelong surveillance so that treatment happens before permanent damage occurs.

43. Treatment Success and Expected Outcomes

Outcomes are generally very good. Balloon valvuloplasty relieves valvular stenosis in the large majority of patients, often permanently, with a low complication rate. Pulmonary valve replacement — surgical or transcatheter — reliably eliminates regurgitation, halts RV dilation and frequently allows the right ventricle to recover, especially when done before severe enlargement.

Symptoms such as breathlessness and fatigue usually improve, and exercise capacity increases. Bioprosthetic and transcatheter valves are durable but not lifelong, so some patients will need a further, usually minimally invasive, valve procedure over the decades. Results are best at high-volume specialist centres.

44. Prognosis and Long-Term Outlook

The long-term outlook for pulmonary valve disease is generally excellent, particularly for isolated pulmonary stenosis treated in childhood — many such patients enjoy a normal life expectancy and quality of life. Successful relief of stenosis is often a durable, near-curative result.

For patients with pulmonary regurgitation after congenital repair, the prognosis depends heavily on timing. When valve replacement is performed before the right ventricle becomes severely dilated or weakened, the RV commonly recovers and long-term outcomes are favourable. If intervention is delayed until RV damage is advanced, some limitation and a higher arrhythmia risk may persist despite a technically successful procedure.

Overall, most people with modern, well-timed treatment live full, active lives. Lifelong follow-up in an adult congenital or valve clinic is essential, both to monitor the right ventricle and to plan any future valve re-intervention. The main long-term considerations are prosthesis durability, arrhythmia management and endocarditis prevention — all of which are well managed with structured care.

45. Recovery and Rehabilitation

Balloon valvuloplasty: usually an overnight stay; most people resume normal activity within a few days, avoiding heavy exertion briefly.
Transcatheter valve replacement: a short hospital stay and recovery over one to two weeks.
Open surgical valve replacement: typically 4–7 days in hospital and 6–8 weeks for fuller recovery, with wound-care and gradual return to activity.
Cardiac rehabilitation — a supervised programme of graded exercise and education helps restore fitness and confidence, especially after surgery.

46. Follow-Up Tests and Long-Term Monitoring

Lifelong follow-up is essential. Typical surveillance includes periodic echocardiograms to assess the valve or prosthesis, cardiac MRI to track RV volumes and function, ECGs and Holter monitoring for arrhythmias, and exercise testing. After valve replacement, the durability of the prosthesis is watched so any future valve-in-valve procedure can be planned electively. Patients also receive endocarditis-prevention advice.

47. Managing Recurrence or Disease Progression

Recurrent obstruction after valvuloplasty, or degeneration of a bioprosthetic/conduit valve years later, is managed proactively. Options include repeat balloon dilation, valve-in-valve transcatheter replacement, or repeat surgery when needed. Arrhythmias may require medication, catheter ablation or a device. Because re-intervention is often anticipated over a lifetime, the strategy is to keep each intervention as minimally invasive as possible and to act before symptoms or RV decline set in.

48. Living with the Disease

Most people with treated or mild pulmonary valve disease live full, active lives. Key habits include attending all follow-up appointments, taking prescribed medicines, practising good dental and skin hygiene to prevent endocarditis, carrying details of any prosthesis, and knowing which symptoms to report. Staying physically active within advised limits, not smoking, and managing weight all support right-heart health. A well-informed patient who partners with their care team generally does very well.

49. Diet and Nutrition Guidelines

Eat a balanced, heart-healthy diet rich in vegetables, fruit, whole grains and lean protein.
Limit salt if you have any fluid retention or right-heart failure, to reduce swelling.
Maintain a healthy weight to lessen the load on the heart.
If taking warfarin, keep vitamin-K intake (leafy greens) consistent and follow INR monitoring.
Limit alcohol, which can trigger arrhythmias, and stay well hydrated as advised.

50. Exercise and Physical-Activity Guidelines

Regular moderate exercise — walking, cycling, swimming — is encouraged for most patients and improves fitness and wellbeing. The safe level depends on severity: those with mild disease or a good result after treatment can usually be fully active, including many competitive sports. Patients with severe stenosis, significant RV dysfunction or arrhythmias may be advised to avoid intense or heavy static exertion until treated. Always obtain an individual activity prescription from your cardiologist, ideally informed by exercise testing.

51. Medications, Activities and Habits to Avoid

Do not smoke — it harms the heart and lungs.
Avoid strenuous, high-intensity or heavy weight-lifting if you have severe untreated disease, until cleared.
Be cautious with decongestants, stimulants and some over-the-counter or recreational drugs that can provoke arrhythmias.
Do not skip endocarditis prophylaxis before dental/surgical work if it has been advised.
Avoid excess alcohol and unmonitored high-dose supplements.
Do not stop prescribed anticoagulants or heart medicines without medical advice.

52. Preventing the Disease or Reducing Its Risks

Congenital pulmonary valve disease cannot usually be prevented, but risks can be reduced. During pregnancy, good prenatal care, avoiding harmful medications, controlling diabetes, ensuring rubella immunity and avoiding alcohol and smoking lower the chance of congenital defects. Genetic counselling helps families with known syndromes.

For acquired disease and complications, prevention focuses on endocarditis prophylaxis, prompt treatment of infections, good dental hygiene, and — crucially — lifelong surveillance after congenital repair so that regurgitation is treated before it damages the heart.

53. Pregnancy and the Disease

Many women with mild disease or a good result after treatment tolerate pregnancy well. However, pregnancy increases blood volume and cardiac workload, which can stress a right ventricle affected by severe stenosis or regurgitation. Pre-pregnancy counselling with a cardiologist is strongly advised; severe stenosis is ideally treated (often by balloon valvuloplasty) before conception. Pregnancy should be managed by a joint obstetric-cardiology team, with monitoring throughout. Genetic counselling is offered where a heritable syndrome is present.

54. Disease in Children and Young Adults

Pulmonary valve disease is fundamentally a paediatric and young-adult condition. Pulmonary stenosis is often diagnosed in infancy via a murmur or newborn screening; balloon valvuloplasty is a highly effective, minimally invasive cure for typical valvular stenosis in children. Critical stenosis in newborns needs urgent treatment. Young adults who had Tetralogy of Fallot or other repairs in childhood must transition to adult congenital heart disease clinics for lifelong monitoring of regurgitation and timely valve replacement. In children, growth potential and the wish to delay prosthetic valves influence timing.

55. Disease in Older Adults

Older patients are usually long-term survivors of congenital repair now developing late regurgitation, arrhythmias or right-heart failure, or occasionally have acquired disease (carcinoid, degenerative changes). Coexisting coronary, lung or kidney disease affects treatment decisions and raises procedural risk. Transcatheter valve replacement is especially valuable here, offering an effective, lower-risk alternative to repeat open surgery. Comprehensive assessment of overall health guides whether and how to intervene.

56. Emotional Health and Patient Support

Living with a lifelong heart condition — and facing possible procedures — can cause anxiety, low mood or stress, particularly for young adults with congenital disease and for parents of affected children. It helps to seek clear information, connect with patient support groups and adult congenital heart networks, and ask for psychological support when needed. Family involvement, peer stories and open communication with the care team all improve wellbeing and confidence.

57. Preparing for Your Specialist Appointment

Bring previous records — operative notes, prior echo/MRI reports, and details of any implanted valve or device.
List your symptoms, when they occur and how they limit you.
Note all medications, allergies and dental/surgical procedures planned.
Record your family and congenital history.
Write down questions in advance and, if possible, bring a companion.

58. Questions to Ask Your Doctor

Do I have pulmonary stenosis, regurgitation, or both, and how severe is it?
How is my right ventricle — is it enlarged or weakened?
Do I need treatment now, or can we safely monitor?
Am I a candidate for a catheter-based (balloon or Melody/Sapien) procedure, or do I need surgery?
What are the benefits and risks of each option for me?
If I have a valve replaced, how long is it likely to last, and what happens when it wears out?
How often will I need follow-up scans, and which ones?
What symptoms should prompt me to contact you urgently?
Do I need antibiotics before dental work to prevent endocarditis?
What are your centre’s experience and outcomes for this procedure?

59. Cost of Diagnosis and Treatment

Costs vary widely by country, hospital and procedure. The figures below are approximate and for guidance only.

Region	Balloon valvuloplasty (approx.)	Pulmonary valve replacement (surgical/transcatheter, approx.)
United States	$15,000–$40,000	$60,000–$180,000+
United Kingdom (private)	£8,000–£20,000	£30,000–£80,000+
India	$3,000–$7,000	$8,000–$25,000
Turkey	$4,000–$9,000	$12,000–$30,000
Thailand	$5,000–$10,000	$15,000–$35,000
Singapore	$8,000–$16,000	$30,000–$70,000

Medical-tourism destinations such as India, Turkey and Thailand often cost roughly 50–90% less than the US or UK for comparable quality at accredited centres. Explore destinations and hospitals for detailed quotes.

60. Factors Affecting Treatment Cost

Type of procedure — balloon vs surgical vs transcatheter valve replacement.
Device used — Melody, Sapien and homograft valves differ substantially in price.
Hospital and country, and level of accreditation (e.g., JCI).
Surgeon/operator experience and centre volume.
Length of stay and ICU care, and any concurrent procedures.
Pre-operative imaging (MRI, CT) and post-operative follow-up.
Complications and need for future re-intervention.
For international patients: travel, accommodation and interpreter costs.

61. Choosing the Right Specialist

Look for a congenital or valve cardiologist and congenital cardiac surgeon with specific experience in pulmonary valve disease and RVOT interventions. Consider:

Sub-specialty training in adult congenital heart disease and structural intervention.
A high personal and centre volume of pulmonary valve procedures.
Availability of both surgical and transcatheter options (so the choice is unbiased).
Transparent outcome data and good patient communication.

Browse experienced doctors to compare specialists.

62. Choosing the Right Hospital or Treatment Centre

Choose a centre with a dedicated congenital/structural heart programme and a full heart team.
Look for international accreditation such as JCI, and strong published outcomes.
Ensure availability of advanced imaging (cardiac MRI, CT), a hybrid cath lab, and on-site cardiac surgical backup.
Prefer high-volume centres, which generally have lower complication rates.
For international patients, confirm medical-travel support and follow-up arrangements.

Compare accredited hospitals and destinations.

63. Getting a Second Medical Opinion

A second opinion is valuable before any valve procedure, especially given the choice between surgical and transcatheter approaches and the importance of timing. Another specialist can confirm the severity, review your imaging, and ensure the least invasive suitable option is being offered. Reputable centres welcome second opinions. You can request a second opinion through our team.

64. Treatment Abroad and Medical-Travel Considerations

Many patients travel for high-quality, more affordable pulmonary valve treatment. When planning care abroad:

Choose an accredited (JCI) centre with a proven congenital/valve programme.
Share your imaging and records in advance for remote assessment and planning.
Plan for adequate recovery time before flying, particularly after surgery.
Arrange follow-up and imaging back home, and clear communication between teams.
Clarify costs, what is included, and contingency for complications.

Explore destinations and treatments for medical-travel options.

65. Frequently Asked Questions

Is pulmonary valve disease serious? It ranges from harmless (mild) to serious. Mild disease often needs only monitoring, while severe stenosis or regurgitation can strain the heart and requires treatment.

Is pulmonary stenosis curable? Typical valvular stenosis is often effectively cured by balloon valvuloplasty, a minimally invasive catheter procedure.

Why do people develop a leaky pulmonary valve after Tetralogy of Fallot repair? The valve is deliberately opened during repair, which commonly leaves lifelong regurgitation that may need a valve replacement later.

Will I need open-heart surgery? Not always. Many patients are treated by catheter-based balloon valvuloplasty or transcatheter valve replacement (Melody/Sapien), avoiding open surgery.

How long do replacement pulmonary valves last? Tissue and transcatheter valves are durable but not permanent; they may last many years, and a worn valve can often be treated with a valve-in-valve catheter procedure.

Can I exercise? Most patients can and should exercise; the safe level depends on severity, so get an individual plan from your cardiologist.

Can I have children if I have this condition? Many women can, but severe disease should ideally be treated first and pregnancy managed by an obstetric-cardiology team.

66. Patient Stories and Treatment Experiences

The following are representative, anonymised illustrations, not specific individuals.

Aarav, India: Diagnosed with valvular pulmonary stenosis as a toddler after a murmur was heard. A single balloon valvuloplasty relieved the narrowing, and he now plays sport with no restrictions.
Sophie, UK: Had Tetralogy of Fallot repaired as a baby. In her twenties, routine MRI showed severe regurgitation with an enlarging right ventricle. A transcatheter pulmonary valve was implanted without open surgery, and her breathlessness resolved.
Miguel, Spain: In his fifties with a degenerated childhood conduit, he underwent a valve-in-valve procedure abroad at an accredited centre, avoiding repeat open surgery and returning to work within two weeks.

67. Latest Research and Clinical Trials

Research is advancing rapidly, focused on making treatment safer, more durable and less invasive. Key directions include self-expanding transcatheter valves for large native outflow tracts (extending catheter therapy to more patients), more durable and tissue-engineered valves, and refined cardiac-MRI thresholds to time valve replacement optimally so the right ventricle recovers. Work also continues on arrhythmia risk prediction and ablation in repaired congenital hearts. Patients interested in trials should ask their adult congenital heart disease centre; reputable programmes can advise on suitable studies. (No specific study data is cited here.)

70. Medical Glossary

Pulmonary valve: the valve between the right ventricle and pulmonary artery.
Pulmonary stenosis (PS): narrowing of the pulmonary valve.
Pulmonary regurgitation (PR): backward leakage through the valve.
Right ventricle (RV): the chamber that pumps blood to the lungs.
RVOT: right ventricular outflow tract, the channel leading to the valve.
Balloon valvuloplasty: catheter balloon procedure to widen a narrowed valve.
TPVR: transcatheter pulmonary valve replacement.
Melody / Sapien valves: transcatheter valves used in the pulmonary position.
Homograft / conduit: a donor or valved tube used to reconstruct the RVOT.
Regurgitant fraction: the proportion of blood leaking backward, measured on MRI.
Tetralogy of Fallot: a congenital defect whose repair often causes later PR.
Dysplastic valve: a thickened, poorly mobile valve, common in Noonan syndrome.
Transannular patch: a surgical patch across the valve ring that can leave regurgitation.
Valve-in-valve: implanting a new catheter valve inside a failed prosthesis.
Endocarditis: infection of a heart valve or prosthesis.

71. Medical Review, Editorial Policy and Last Updated Date

Last updated: 11 July 2026.

This article is reviewed for accuracy against current cardiology and congenital heart disease guidance (ACC/AHA, ESC, NHS and specialist society sources) as part of our editorial policy. Content is written and reviewed by qualified medical writers and clinicians, updated periodically, and referenced to reputable guideline bodies.

Disclaimer: This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider about your individual condition.

72. Clinical Guidelines and Medical References

General guidance is drawn from recognised bodies, including:

American College of Cardiology / American Heart Association (ACC/AHA) valvular and adult congenital heart disease guidelines.
European Society of Cardiology (ESC) guidelines on valvular and adult congenital heart disease.
UK National Health Service (NHS) patient information.
Society of Thoracic Surgeons (STS) resources.
World Health Organization (WHO) and specialist congenital heart disease societies.

These are cited in general terms; please consult the current published guidelines and your care team for specifics.

73. Book an Appointment or Request a Second Opinion

Ready to take the next step? Our team can help you find leading specialists and accredited hospitals for pulmonary valve disease, arrange expert opinions, and plan treatment at home or abroad.

Book an appointment: /contact/
Request a second opinion or ask a question: Contact us

Explore top hospitals, experienced doctors, and popular destinations to begin your care journey with confidence.

Pulmonary Valve Disease